{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:19:15Z","timestamp":1747196355938,"version":"3.40.5"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"Tuberculosis Epidemiologic Studies Consortium of CDC and by other CDC projects"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Studying treatment duration for rifampicin-resistant and multidrug-resistant tuberculosis (MDR\/RR-TB) using observational data is methodologically challenging. We aim to present a hypothesis generating approach to identify factors associated with shorter duration of treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Study design and setting<\/jats:title>\n<jats:p>We conducted an individual patient data meta-analysis among MDR\/RR-TB patients restricted to only those with successful treatment outcomes. Using multivariable linear regression, we estimated associations and their 95% confidence intervals (CI) between the outcome of individual deviation in treatment duration (in months) from the mean duration of their treatment site and patient characteristics, drug resistance, and treatments used.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 6702 patients with successful treatment outcomes from 84 treatment sites were included. We found that factors commonly associated with poor treatment outcomes were also associated with longer treatment durations, relative to the site mean duration. Use of bedaquiline was associated with a 0.51 (95% CI: 0.15, 0.87) month decrease in duration of treatment, which was consistent across subgroups, while MDR\/RR-TB with fluoroquinolone resistance was associated with 0.78 (95% CI: 0.36, 1.21) months increase.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We describe a method to assess associations between clinical factors and treatment duration in observational studies of MDR\/RR-TB patients, that may help identify patients who can benefit from shorter treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0292106","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:55:02Z","timestamp":1696528502000},"page":"e0292106","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-4381","authenticated-orcid":true,"given":"Nicholas","family":"Winters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille E.","family":"Schnitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon R.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Ripley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Winston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rada","family":"Savic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6202-4345","authenticated-orcid":true,"given":"Nafees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Esmail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medea","family":"Gegia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Monedero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6820-1082","authenticated-orcid":true,"given":"Margareth Pretti","family":"Dalcolmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupak","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"volume-title":"Global tuberculosis report 2022","year":"2022","author":"World Health Organization","key":"pone.0292106.ref001"},{"issue":"5","key":"pone.0292106.ref002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01394-2020","article-title":"Changes in treatment for multidrug-resistant tuberculosis according to national income","volume":"56","author":"N Kwak","year":"2020","journal-title":"Eur Respir J"},{"volume-title":"WHO operational handbook on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment","year":"2022","author":"World Health Organization","key":"pone.0292106.ref003"},{"issue":"8","key":"pone.0292106.ref004","doi-asserted-by":"crossref","first-page":"e044698","DOI":"10.1136\/bmjopen-2020-044698","article-title":"Experiences and needs of patients with MDR\/XDR-TB: a qualitative study among Saharia tribe in Madhya Pradesh","volume":"11","author":"S Nigam","year":"2021","journal-title":"Central India. BMJ Open"},{"issue":"8","key":"pone.0292106.ref005","doi-asserted-by":"crossref","first-page":"e0135802","DOI":"10.1371\/journal.pone.0135802","article-title":"Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India","volume":"10","author":"RD Deshmukh","year":"2015","journal-title":"PloS one"},{"issue":"3","key":"pone.0292106.ref006","doi-asserted-by":"crossref","first-page":"e0150849","DOI":"10.1371\/journal.pone.0150849","article-title":"\"When Treatment Is More Challenging than the Disease\": A Qualitative Study of MDR\/RR-TB Patient Retention","volume":"11","author":"KS Shringarpure","year":"2016","journal-title":"PloS one"},{"issue":"1","key":"pone.0292106.ref007","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00622-2021","article-title":"Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan","volume":"8","author":"S Kohler","year":"2022","journal-title":"ERJ Open Res"},{"issue":"5","key":"pone.0292106.ref008","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"A Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"pone.0292106.ref009","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis","volume":"380","author":"AJ Nunn","year":"2019","journal-title":"N Engl J Med"},{"issue":"10366","key":"pone.0292106.ref010","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"RL Goodall","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"pone.0292106.ref011","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis","volume":"387","author":"F Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"10362","key":"pone.0292106.ref012","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","article-title":"9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea","volume":"400","author":"J Mok","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"pone.0292106.ref013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses","volume":"50","author":"F Ahmad Khan","year":"2017","journal-title":"Eur Respir J"},{"volume-title":"Consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019","author":"World Health Organization","key":"pone.0292106.ref014"},{"key":"pone.0292106.ref015","unstructured":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018; 392(10150): 821\u201334."},{"issue":"3","key":"pone.0292106.ref016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00803-2016","article-title":"An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis","volume":"49","author":"ML Bastos","year":"2017","journal-title":"Eur Respir J"},{"issue":"8","key":"pone.0292106.ref017","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"SD Ahuja","year":"2012","journal-title":"PLoS medicine"},{"key":"pone.0292106.ref018","unstructured":"World Health Organization. Public call for individual patient data on treatment of rifampicin and multidrug-resistant (MDR\/RR-TB) tuberculosis.. 2018. https:\/\/www.who.int\/news-room\/articles-detail\/public-call-for-individual-patient-data-on-treatment-of-rifampicin-and-multidrug-resistant-(mdr-rr-tb)-tuberculosis (accessed 10 Nov 2022."},{"key":"pone.0292106.ref019","unstructured":"World Health Organization. Public call for individual patient data on treatment of drug-resistant tuberculosis. 2019. https:\/\/www.who.int\/news\/item\/01-08-2019-public-call-for-individual-patient-data-on-treatment-of-drug-resistant-tuberculosis (accessed 10 Nov 2022."},{"issue":"10248","key":"pone.0292106.ref020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0140-6736(20)31316-7","article-title":"Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis","volume":"396","author":"GP Bisson","year":"2020","journal-title":"Lancet"},{"key":"pone.0292106.ref021","article-title":"Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis","author":"JR Campbell","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0292106.ref022","first-page":"640","article-title":"Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis","volume":"9","author":"KF Laserson","year":"2005","journal-title":"The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease"},{"volume-title":"Definitions and reporting framework for tuberculosis\u20142013 revision","year":"2013","author":"World Health Organization","key":"pone.0292106.ref023"},{"issue":"3","key":"pone.0292106.ref024","first-page":"1","article-title":"mice: Multivariate Imputation by Chained Equations in R","volume":"45","author":"S van Buuren","year":"2011","journal-title":"Journal of Statistical Software"},{"issue":"476","key":"pone.0292106.ref025","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1198\/016214506000000735","article-title":"The Adaptive Lasso and Its Oracle Properties","volume":"101","author":"H. Zou","year":"2006","journal-title":"Journal of the American Statistical Association"},{"issue":"4","key":"pone.0292106.ref026","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E-Value","volume":"167","author":"TJ VanderWeele","year":"2017","journal-title":"Annals of internal medicine"},{"key":"pone.0292106.ref027","unstructured":"R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, URL https:\/\/wwwR-projectorg\/."},{"issue":"7","key":"pone.0292106.ref028","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study","volume":"22","author":"N Ndjeka","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"pone.0292106.ref029","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"F Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0292106.ref030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"K Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"pone.0292106.ref031","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S0266466605050036","article-title":"Model Selection and Inference: Facts and Fiction","volume":"21","author":"H Leeb","year":"2005","journal-title":"Econometric Theory"},{"issue":"8","key":"pone.0292106.ref032","doi-asserted-by":"crossref","first-page":"649","DOI":"10.5588\/ijtld.23.0185","article-title":"Initial experience with BPaL-based regimens to treat multidrug-resistant TB","volume":"27","author":"C Acuna-Villaorduna","year":"2023","journal-title":"The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease"},{"key":"pone.0292106.ref033","article-title":"Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease","author":"CA Haley","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:55:22Z","timestamp":1696528522000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0292106"}},"subtitle":[],"editor":[{"given":"Dzintars","family":"Gotham","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0292106","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,10,5]]}}}